Baker Bros. Advisors LP Biomarin Pharmaceutical Inc Transaction History

Baker Bros. Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $334 Million - $447 Million	-3,810,246 Reduced 50.0%	3,810,248 $371 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $2.33 Million - $2.67 Million	31,200 Added 0.41%	7,620,494 $589 Million
Q4 2018 Feb 13, 2019	BUY	$80.14 - $106.07 $497,669 - $658,694	6,210 Added 0.08%	7,589,294 $646 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $135 Million - $160 Million	1,677,411 Added 28.4%	7,583,084 $676 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $476 Million - $561 Million	5,905,673	5,905,673 $550 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.